Successful Treatment of Scleromyxedema With Autologous Peripheral Blood Stem Cell Transplantation

Scleroderma-like Fibrosing Disorders

“…These conflicting data would perhaps suggest that the measurable paraprotein does not have a direct role in the pathogenesis of scleromyxedema through direct tissue fibroblast stimulation. A study of 5 patients who underwent peripheral blood stem cell transplant (PBSCT) showed that only 2 patients had an eradication of their monoclonal protein and that there was no relationship between clinical improvement and monoclonal band disappearance (53). Additionally, as we and others have observed, the level of paraprotein does not decrease even after effective treatment, and there seems to be no dose-dependant relationship between paraprotein quantity and clinical effects.…”

“…There are multiple cases describing some benefit using thalidomide, although there remains a legitimate concern for the development of disabling peripheral neuropathy (68)(69)(70)(71)(72). More recent data note benefit of autologous stem cell transplantation in recalcitrant cases (53,(73)(74)(75).…”

Dermato-Neuro Syndrome in a Patient Treated With Autologous Stem Cell Transplant for Scleromyxedema

“…A decision was made to proceed with high-dose therapy and autologous stem cell transplantation, based on reports of benefit in this and related plasma cell dyscrasias. 6,7 Autologous hematopoietic progenitor cells were mobilized after granulocyte colony stimulating factor (GCSF) administration and the product was cryopreserved. She went on to receive conditioning chemotherapy consisting of melphalan 200 mg/m 2 , followed by reinfusion of autologous cells.…”

Paraneoplastik özellik gösteren metabolik hastalıklar

“…Yüksek doz kemoterapi ve kök hücre transplantasyonu ise tedavi edici olmamakla beraber uzun süreli remisyon sağlayabilmektedir 2 . Bu tedavi modeli kök hücre tedavisine engel olacak sitostatik bir tedavi verilmeden önce planlanmalıdır 9 . Remisyon süresini uzatabilmek için farklı kemoterapi Aydıngöz ve ark.…”